Trial Profile

An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rovalpituzumab tesirine (Primary)
Indications Gastrointestinal cancer; Glioblastoma; Large cell carcinoma; Malignant melanoma; Neuroendocrine carcinoma; Pancreatic cancer; Prostate cancer; Solid tumours; Thyroid cancer
Focus Adverse reactions
Sponsors AbbVie; Stem CentRx

Most Recent Events

31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
29 Aug 2019 Status changed from active, no longer recruiting to discontinued.According to an AbbVie media release, the company discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
21 May 2019 Planned End Date changed from 1 Sep 2020 to 27 Aug 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com